GlassScriptPhysician profile
Asaff Harel
NPI 1487945465
$179,144.54
in general payments reported to CMS, 2019-2025
15 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $10K · 2021: $6,450 · 2022: $6,566 · 2023: $33K · 2024: $46K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $18K · Honoraria: $11K · Travel and Lodging: $8,302 · Food and Beverage: $4,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,595.00 |
| Consulting Fee | $17,840.00 |
| Honoraria | $10,650.00 |
| Travel and Lodging | $8,301.77 |
| Food and Beverage | $4,989.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $85,961.97 | 2020-2025 | Ultomiris, Soliris |
| Amgen INC. | $37,634.04 | 2024-2025 | Uplizna |
| Tg Therapeutics, INC. | $18,572.48 | 2024-2025 | |
| Horizon Therapeutics Plc | $13,999.69 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $8,045.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,466.87 | 2025 | |
| Biogen, INC. | $5,421.71 | 2019-2023 | Tysabri |
| Banner Life Sciences, LLC | $1,700.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $485.90 | 2019-2024 | |
| Celgene Corporation | $478.90 | 2025 | |
| Genentech, INC. | $130.33 | 2024 | Ocrevus |
| Emd Serono, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $122.60 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asaff Harel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.